Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial

Neurology

Volumn 45, Issue 7, 1995, Pages 1268-1276

  Johnson, Kenneth P ^a   Brooks, B R ^b   Cohen, J A ^c   Ford, C C ^d   Goldstein, J ^e   Lisak, R P ^f   Myers, L W ^g   Panitch, H S ^a   Rose, J W ^h   Schiffer, R B ⁱ   Vollmer, T ^e   Weiner, L P ^g   Wolinsky, J S ^j   Bird, Shawn J ^k   Kolson, Dennis L ^k   Gonzalez–scarano, Francisco ^k   Brennan, Daniel ^k   Pfohl, Dorothea ^k   Mandler, Raul N ^l   Rosenberg, Gary A ^l   Jeffrey, Carol ^l   Barger, Geoffrey R ^m   Gandhi, Balbir ^m   Moore, Patricia M ^m   Rogers, Lisa R ^m   Lisak, Deena ^m   Smith, Lissa ^m   Ellison, George W ⁿ   Baumhefner, Robert W ⁿ   Craig, Sharon L ⁿ   Jalbut, Suhayl S ^o   Katz, Eleanor ^o   Conway, Kathleen L S ^o   Burns, James B ^h   Shiba, Connie ^h   Giang, Daniel W ^p   Petrie, Mary D ^p   Guarnaccia, Joseph B ^e   Anderson, Susan ^e   Mc Keon, Anne ^e   Mc Carthy, Micheline ^j   Thomas, Azreena B ^j   Vriesendorp, Francine J ^j   Austin, Sara G ^j   Lindsey, John W ^j   Dimachkie, Mazen ^j   Cerreta, Emily ^j   Kachuck, Norman ^q   Mc Carthy, Kathleen A ^q   Fleming, John ^b   Parnell, Jennifer H ^b   Tamulevich, Jennifer ^b   Weasler, Christy ^b   Kadosh, Shaul ^r   Hait, Howard ^r   Stark, Yafit ^r   Pinchasi, Irit ^r   Spiller, Nina ^s   Van Den Noort, Stanley ^t   Miller, Aaron ^u   Mellits, David ^v   Reingold, Stephen ^w   Gomolin, Irving H ^x   more..

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e YALE UNIVERSITY   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ UNIVERSITY OF ROCHESTER   (United States)

^j UNIVERSITY OF TEXAS   (United States)

^k HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^l UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^m WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^q UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^r TEVA PHARMACEUTICALS   (Israel)

^s University of Texas at Houston ^*  (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u MAIMONIDES MEDICAL CENTER   (United States)

^v JOHNS HOPKINS HOSPITAL   (United States)

^w National Multiple Sclerosis Society   (United States)

^x Gurwin Jewish Geriatric Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COPOLYMER; GLATIRAMER;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART PALPITATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INJECTION PAIN; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECURRENCE RISK; RELAPSE; SCORING SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION; THORAX PAIN;

ADULT; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; PEPTIDES; RECURRENCE;

EID: 0029082566     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.45.7.1268     Document Type: Article

References (22)

1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
2. IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo- controlled trial. Neurology 1993;43:655-661.
3. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971;1:242-248.
4. Teitelbaum D, Webb C, Bree M, Meshorer A, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol 1974;3:256-262.
5. Webb C, Teitelbaum D, Arnon R, Sela M. In vivo and in vitro immunological cross-reactions between basic encepha- litogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur J Immunol 1973;3:279-286.
6. Abramsky O, Teitelbaum D, Arnon R. Effect of a synthetic polypeptide (copolymer 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis. J Neurol Sci 1977;31:433-438.
7. Bornstein MB, Miller AI, Teitelbaum D, Arnon R, Sela M. Multiple sclerosis: trial of a synthetic polypeptide. Ann Neurol 1982;11:317-319.
8. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of copolymer 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317:408-414.
9. Bornstein MB, Miller A, Slagle S, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991;41: 533-539.
10. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
11. Arnon R. Experimental allergic encephalomyelitis-susceptibility and suppression. Immunol Rev 1981;55:5-30.
12. Teitelbaum D, Aharoni R, Sela M, Arnon R. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc Natl Acad Sci USA 1991;88:9528-9532.
13. Burns J, Krasner J, Guerrero F. Human cellular immune response to copolymer I and myelin basic protein. Neurology 1986;36:92-94.
14. Bums J, Littlefield K. Failure of copolymer I to inhibit the human T-cell response to myelin basic protein. Neurology 1991;41:1317-1319.
15. Lisak RP, Sweiman B, Blanchard N, Rorke LB. Effect of treatment with copolymer I (Cop I) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis. J Neurol Sci 1983;62:281-293.
16. Lando Z, Teitelbaum D, Arnon R. Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol 1979;123:2156-2160.
17. Aharoni R, Teitelbaum D, Arnon R. T suppressor hybrido- mas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis. Eur J Immunol 1993;23: 17-25.
18. Teitelbaum D, Aharoni R, Arnon R, Sela M. Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer 1. Proc Natl Acad Sci USA 1988;85: 9724-9728.
19. Teitelbaum D, Milo R, Arnon R, Sela M. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci USA 1992;89:137-141.
20. Fridkis-Hareli M, Teitelbaum D, Gurevitch E, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen presenting cells-specificity and promiscuity. Proc Natl Acad Sci USA 1994;91:4872-4876.
21. Racke MK, Martin R, McFarland H, Fritz RB. Copolymer 1- induced inhibition of antigen-specific T-cell activation: interference with antigen presentation. J Neuroimmunol 1992; 37:75-84.
22. Milo R, Panitch H. Additive effects of Cop-1 and IFN-beta on immune responses to myelin basic protein [abstract]. Neurology 1994;44(suppl 2):A212-A213.